Clinical trialNCT02128542CompletedPhase 4Interventional

Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis

SponsorGilead SciencesEnrollment66Hepatitis C Virus Infection

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will examine the safety, tolerability, and antiviral efficacy of sofosbuvir (SOF)+ribavirin (RBV) in treatment-naive and treatment-experienced United States Veterans with compensated cirrhosis and genotype 2 HCV infection.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Lorenzo Rossaro, MD
Gilead Sciences
Study DirectorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

17 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Facility name not stated
Long Beach, California, United States
Facility name not stated
Los Angeles, California, United States
Facility name not stated
Palo Alto, California, United States
Facility name not stated
San Diego, California, United States
Facility name not stated
San Francisco, California, United States
Facility name not stated
New Haven, Connecticut, United States
Facility name not stated
Miami, Florida, United States
Facility name not stated
Decatur, Georgia, United States
Facility name not stated
Baltimore, Maryland, United States
Facility name not stated
Kansas City, Missouri, United States
Facility name not stated
Durham, North Carolina, United States
Facility name not stated
Portland, Oregon, United States
Facility name not stated
Philadelphia, Pennsylvania, United States
Facility name not stated
Pittsburgh, Pennsylvania, United States
Facility name not stated
Dallas, Texas, United States
Facility name not stated
Houston, Texas, United States
Facility name not stated
Richmond, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ribavirin →Sofosbuvir →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Jun 2014
Primary completion: 30 Jun 2015
Completion: 30 Jun 2015
Last update posted: 3 Aug 2016
Registered enrollment: 66
Registry id: NCT02128542

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.